OTC · Medical - Distribution

Sinopharm Group Co. Ltd. (SHTDY) Stock

$10.83 -1.81% OTC: SHTDY Healthcare

Sinopharm Group Co. Ltd.

Valuation

MetricValue
Price$10.83
Market Cap$6.76B
P/E Ratio6.40
P/B Ratio0.55
P/S Ratio0.08
EPS (TTM)$1.69
52-Week High$14.87
52-Week Low$10.00
Dividend Yield4.71%

Financials & Margins

MetricValue
ROE8.70%
ROA1.83%
ROCE10.95%
Gross Margin7.32%
Operating Margin2.74%
Net Margin1.24%
Debt/Equity1.29
Current Ratio1.41

Annual Financials (USD)

Metric20212022202320242025
Revenue$521.1B$552.1B$596.6B$584.5B$559.5B
Operating Profit$19.7B$20.6B$20.2B$16.2B$16.2B
Net Profit$7.8B$8.5B$9.1B$7.0B$7.0B
EPS$12.45$13.65$14.50$11.30$11.10
Op Margin3.8%3.7%3.4%2.8%2.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$335.4B$364.8B$383.4B$392.8B$390.6B
Total Liabilities$235.8B$254.7B$263.1B$266.1B$256.4B
Cash$43.5B$55.2B$63.8B$54.3B$61.6B
Borrowings$68.4B$69.6B$73.8B$76.4B$108.7B

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$9.3B$21.0B$17.2B$11.5B$14.1B
Investing Cash Flow$-3.5B$-6.0B$-3.3B$-5.8B$-2.6B
Financing Cash Flow$-7.8B$-8.1B$-7.6B$-4.6B$-5.7B
Net Cash Flow$-6.6B$11.7B$8.6B$-9.5B$-5.5B
Free Cash Flow$7.1B$18.5B$14.8B$9.6B$12.5B

Valuation & Return Ratios

MetricValue
PEG Ratio4.82
EV / EBITDA4.56
FCF Yield22.95%
Quick Ratio1.15
Interest Coverage9.36
Return 1Y-6.19%
Return 3Y-18.16%
Return 5Y-4.19%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
GIFOFGrifols, S.A. $8.85 +0.00% 15.97 $8.70B 1.24%
MSMKFMatsukiyoCocokara & Co. $14.88 +0.00% 17.37 $5.85B 2.28%
SHPMFShanghai Pharmaceuticals Holding Co., Ltd $1.46 +0.00% 10.56 $8.46B 6.85%
SHPMYShanghai Pharmaceuticals Holding Co., Ltd $7.34 +0.00% 10.56 $5.44B 6.95%
SSMXFSysmex Corporation $9.65 +0.00% 26.51 $6.00B 2.59%

About Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharmaceutical Distribution segment is responsible for supplying a wide array of pharmaceutical products to various healthcare entities, including hospitals, clinics, and retail pharmacies. This segment also provides comprehensive logistics and value-added services to both domestic and international manufacturers and suppliers of pharmaceutical and healthcare items. The Medical Devices segment focuses specifically on the distribution of medical equipment. Through its Retail Pharmacy segment, the company operates and franchises an extensive chain of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment encompasses the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core activities, Sinopharm Group also engages in property rental and management, distributes specialized products such as Chinese herbal medicines, antibiotics, and biological products, and offers a suite of services. These include IT development, medicine, business, health, and market information consulting, international trade (import/export of goods and technology), market investigation, and convention and exhibition services. Furthermore, the company is involved in medical project investment, consulting, and technology training. To enhance its commercial capabilities and transformation, Sinopharm Group Co. Ltd. maintains a strategic partnership with I-Mab. Founded in 2003, the company is headquartered in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Sinopharm Group Co. Ltd. is headquartered in CN.

Sinopharm Group Co. Ltd. (SHTDY) stock trades at $10.83 with a market capitalization of $6.76B. The stock is valued at a price-to-earnings (P/E) ratio of 6.40, price-to-book of 0.55, price-to-sales of 0.08. Over the past 52 weeks the stock has ranged between $10.00 and $14.87, and currently trades 27.2% below its 52-week high. It pays a dividend yielding 4.71%.

On profitability, Sinopharm Group Co. Ltd. generates a return on equity (ROE) of 8.70%, return on capital employed of 10.95%, an operating margin of 2.74%, a net profit margin of 1.24%.

Official website: www.sinopharmgroup.com.cn

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides